About this trial
In current practice, options for venous and lymphatic malformations remain limited. Recently an oral medication, sirolimus, has been found to benefit patients when taken once or twice a day for several months. Unfortunately there are many side effects associated with this medication, some of which can be severe including, neutropenia, oral ulcerations, and lab abnormalities. The purpose of this study is to determine if once weekly dosed sirolimus will be effective for the treatment of venous and lymphatic malformations. Additionally, the study will evaluate patient satisfaction and identify adverse effects. Participants will be on the medication for 6 months with an option to continue after this time period.
Eligibility criteria
Qualifiers
Patient 2 years of age and older
Venous, lymphatic, or venolymphatic malformations
Disqualifiers
Children with contraindication to use of sirolimus
Children with history of transplant
Children with a history of natural immunodeficiency
Children with a history of artificially induced immunodeficiency
Trial design
Treatments tested in this trial
- Sirolimus